Skip to content

Study · Non-randomized trial · n = 9 · 1987

18 results

Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I

Digestion1 Jan 1987Cited by 141 (Europe PMC)

PMID2883060 (opens in a new tab)DOI10.1159/000199408 (opens in a new tab)PepBankPUB-02883060
Publisher pagePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

  1. 01HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide increased mean faecal fat excretion to 19.2 g/day versus placebo.

    In plain wordsIn healthy volunteers, octreotide increased average stool fat loss to 19.2 g/day versus placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseFaecal fat excretion
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Mean faecal fat excretion
    19.2 g/day
    during SMS period

    Source sentences

    Summary
    Mean faecal fat excretion was increased to 19.2 g/day and MCTT was three times longer during the SMS period.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  2. 02HumanNon-randomized trialMechanism

    In healthy volunteers, mouth-to-caecum transit was three times longer during octreotide than placebo.

    In plain wordsIn healthy volunteers, gut transit took three times longer with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseMouth-to-caecum transit time
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Mouth-to-caecum transit time ratio
    3 times longer
    SMS period versus placebo period

    Source sentences

    Summary
    Mean faecal fat excretion was increased to 19.2 g/day and MCTT was three times longer during the SMS period.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  3. 03HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide significantly reduced serum D-galactose after a duodenal nutrient infusion versus placebo.

    In plain wordsIn healthy volunteers, octreotide lowered blood D-galactose after nutrients entered the intestine versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum D-galactose after duodenal infusion
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    After duodenal infusion of a mixture containing D-galactose, D-xylose and triglycerides, SMS 201-995 significantly reduced the serum concentrations of D-galactose but increased serum levels of D-xylose.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  4. 04HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide increased serum D-xylose after a duodenal nutrient infusion versus placebo.

    In plain wordsIn healthy volunteers, octreotide increased blood D-xylose after nutrients entered the intestine versus placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseSerum D-xylose after duodenal infusion
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    After duodenal infusion of a mixture containing D-galactose, D-xylose and triglycerides, SMS 201-995 significantly reduced the serum concentrations of D-galactose but increased serum levels of D-xylose.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  5. 05HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide completely suppressed the duodenal trypsin rise after a Lundh meal following 6 days of pretreatment.

    In plain wordsIn healthy volunteers, octreotide blocked the intestinal trypsin rise after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMeal-induced duodenal trypsin increase
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 6 daysAs given in this study (human).

    Source sentences

    Summary
    After 6 days of pretreatment, SMS 201-995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  6. 06HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide completely suppressed the duodenal lipase rise after a Lundh meal following 6 days of pretreatment.

    In plain wordsIn healthy volunteers, octreotide blocked the intestinal lipase rise after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMeal-induced duodenal lipase increase
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 6 daysAs given in this study (human).

    Source sentences

    Summary
    After 6 days of pretreatment, SMS 201-995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  7. 07HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide completely suppressed the duodenal bilirubin rise after a Lundh meal following 6 days of pretreatment.

    In plain wordsIn healthy volunteers, octreotide blocked the intestinal bilirubin rise after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMeal-induced duodenal bilirubin increase
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 6 daysAs given in this study (human).

    Source sentences

    Summary
    After 6 days of pretreatment, SMS 201-995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  8. 08HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide almost abolished CCK release with a Lundh meal versus placebo.

    In plain wordsIn healthy volunteers, octreotide almost blocked CCK release after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMeal-induced CCK release
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 6 daysAs given in this study (human).

    Source sentences

    Summary
    Concomitantly, cholecystokinin (CCK) release and gall bladder contraction were almost abolished.
    2 context sentences
    Summary · context
    After 6 days of pretreatment, SMS 201-995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal.
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  9. 09HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide almost abolished gallbladder contraction with a Lundh meal versus placebo.

    In plain wordsIn healthy volunteers, octreotide almost blocked gallbladder contraction after food versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMeal-induced gallbladder contraction
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 6 daysAs given in this study (human).

    Source sentences

    Summary
    Concomitantly, cholecystokinin (CCK) release and gall bladder contraction were almost abolished.
    2 context sentences
    Summary · context
    After 6 days of pretreatment, SMS 201-995 completely suppressed duodenal trypsin, lipase and bilirubin increases in response to endogenous stimulation by a Lundh meal.
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  10. 10HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide significantly diminished pancreatic amylase output after CCK stimulation versus placebo.

    In plain wordsIn healthy volunteers, octreotide lowered CCK-stimulated pancreatic amylase output versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseCCK-stimulated amylase output
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, SMS 201-995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  11. 11HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide significantly diminished pancreatic trypsin output after CCK stimulation versus placebo.

    In plain wordsIn healthy volunteers, octreotide lowered CCK-stimulated pancreatic trypsin output versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseCCK-stimulated trypsin output
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, SMS 201-995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  12. 12HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide significantly diminished pancreatic lipase output after CCK stimulation versus placebo.

    In plain wordsIn healthy volunteers, octreotide lowered CCK-stimulated pancreatic lipase output versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseCCK-stimulated lipase output
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, SMS 201-995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  13. 13HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide did not change fluid secretion in response to secretin versus placebo.

    In plain wordsIn healthy volunteers, octreotide did not change secretin-stimulated fluid secretion versus placebo.

    Peptide
    Octreotide
    Outcome
    No significant changeSecretin-stimulated fluid secretion
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, SMS 201-995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  14. 14HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide did not change bicarbonate secretion in response to secretin versus placebo.

    In plain wordsIn healthy volunteers, octreotide did not change secretin-stimulated bicarbonate secretion versus placebo.

    Peptide
    Octreotide
    Outcome
    No significant changeSecretin-stimulated bicarbonate secretion
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, SMS 201-995 significantly diminished pancreatic amylase, trypsin and lipase output after stimulation with CCK, while the secretion of fluid and bicarbonate in response to secretin was unchanged.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  15. 15HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide inhibited enzyme response significantly more after a single injection than after 7 days of pretreatment.

    In plain wordsIn healthy volunteers, one octreotide injection suppressed enzyme responses more than octreotide pretreatment for 7 days.

    Peptide
    Octreotide
    Outcome
    DecreaseAcute versus repeated enzyme inhibition
    Study

    n = 9

    Comparator
    Octreotide pretreatment for 7 days
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms once · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    This inhibition of enzyme response was significantly more marked after a single injection of the analogue than after pretreatment for 7 days and did not reach the level of exocrine pancreatic insufficiency.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  16. 16HumanNon-randomized trialSafety outcome

    In healthy volunteers, enzyme inhibition with octreotide did not reach the level of exocrine pancreatic insufficiency.

    In plain wordsIn healthy volunteers, octreotide enzyme inhibition did not reach the level of pancreatic insufficiency.

    Peptide
    Octreotide
    Outcome
    Not applicableExocrine pancreatic insufficiency
    Study

    n = 9

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    25 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    This inhibition of enzyme response was significantly more marked after a single injection of the analogue than after pretreatment for 7 days and did not reach the level of exocrine pancreatic insufficiency.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  17. 17HumanNon-randomized trialMechanism

    In healthy volunteers, a single octreotide dose significantly inhibited CCK-induced gallbladder contraction versus placebo.

    In plain wordsIn healthy volunteers, one octreotide dose reduced CCK-induced gallbladder contraction versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseAcute CCK-induced gallbladder contraction
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms once · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    CCK-induced gall bladder contraction was significantly inhibited by a single dose of 25 micrograms SMS 201-995 but not after 7 days of pretreatment with the somatostatin analogue.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.
  18. 18HumanNon-randomized trialMechanism

    In healthy volunteers, octreotide did not significantly inhibit CCK-induced gallbladder contraction after 7 days of pretreatment.

    In plain wordsIn healthy volunteers, octreotide did not significantly reduce CCK-induced gallbladder contraction versus placebo after 7 days of pretreatment.

    Peptide
    Octreotide
    Outcome
    No significant changeCCK-induced gallbladder contraction after pretreatment
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    25 micrograms twice daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    CCK-induced gall bladder contraction was significantly inhibited by a single dose of 25 micrograms SMS 201-995 but not after 7 days of pretreatment with the somatostatin analogue.
    1 context sentence
    Summary · context
    In a double-blind cross-over study, 9 healthy volunteers completed two 7-day periods with subcutaneous injections of either placebo or 25 micrograms SMS 201-995 twice daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.